What We Do

Prinston Pharma is an integrated pharmaceutical company in the United States that develops, manufactures, and markets high-quality and affordable generic medicines. Headquartered in Somerset, New Jersey, Prinston Pharma boasts world-class capability in generic drug R&D, cGMP manufacturing, and Sales & Marketing. With years of transformation-upgrading and industrial restructuring, Prinston has established a complete supply chain of APIs and pharmaceutical products, along with large manufacturing bases globally.

Our highly experienced R&D team meets market needs through innovation, in order to bring quality products to the US market and to help patients reduce their medical costs. We have developed an extensive portfolio of products in therapeutic areas that include cardiovascular disease, CNS disease, viral disease, and oncology.

US manufacturing work is done through our subsidiary Prinston Lab, which is located in Charlotte, North Carolina. We have capability in the production of a variety of capsules and tablets. Moreover, this cGMP facility is licensed by the United States Drug Enforcement Agency (DEA) for handling of controlled substances including those in Schedules II, III, IV, and V.

Our sales and marketing effort is spearheaded by Solco Healthcare, our wholly-owned subsidiary. Solco offers a broad range of FDA-approved generic prescription products in various therapeutic areas, including cardiovascular, diabetes, and central nervous system products. We currently market about 90 products in the country, with an additional 40 products pending approval by the FDA, and a robust R&D pipeline of potential new products. These drugs are distributed through pharmacies like CVS and Walgreen, department stores such as Walmart and Costco, and major grocery stores.

Prinston Pharma employs close to 200 employees in this country, mostly in the states of New Jersey and North Carolina.

The corporate parent of Prinston Pharma is Zhejiang Huahai Pharmaceutical, Inc, a world-leader in active pharmaceutical ingredients (API) and finished dosage products, and is a publicly listed company in the Shanghai Stock Exchange.